Tate & Lyle invests in new born pre/probiotics

20 Aug 2015

Tate & Lyle Ventures has announced a $2 million investment in Evolve BioSystems,. a microbiome spin-out company from the University of California at Davis. According to Tate & Lyle, Evolve is developing revolutionary science in the field of probiotics and prebiotics for new born infants during the crucial early months of development. This investment is […]

Tate & Lyle invests in new born pre/probiotics

money-stack-dollars-d-illustration-51189217Tate & Lyle Ventures has announced a $2 million investment in Evolve BioSystems,. a microbiome spin-out company from the University of California at Davis. According to Tate & Lyle, Evolve is developing revolutionary science in the field of probiotics and prebiotics for new born infants during the crucial early months of development.

This investment is part of the Tate & Lyle Venture Fund which was established in 2013 to invest up to £30 million over an eight-year period in start-ups and expansion-stage companies in food sciences and enabling technologies in line with Tate & Lyle’s strategy to grow in speciality food ingredients.
Evolve was established by researchers from the University of California at Davis based on a decade of research into the developing infant microbiome and its relationship with the natural nutrients in human breast milk. Evolve has a proprietary combination of activated probiotic bacteria, prebiotics and delivery systems to provide, restore and maintain a healthy microbiome in infants during the first six months of life – with particular focus on those born prematurely, delivered by Caesarian section or fed exclusively with formula milk.

The funds will be applied to support Evolve’s ongoing clinical activities, operational expansion, and preparations for commercial launch of its novel probiotic and prebiotic products, which restore the balance of the infant microbiota.

“Having originally invested in Evolve in August 2014, we are delighted to support the company as it progresses its research, clinical, and commercial endeavours,” said Dr. Simon Barnes, Managing Partner of Tate and Lyle Ventures, and a member of the Board of Directors of Evolve. “Over the past year the Evolve management team has raised seed capital, licensed a substantial suite of intellectual property from the University of California, initiated clinical trials, and commenced business development activities for a range of products and technologies being developed by the company.”